Cargando…

Safety of hookworm infection in individuals with measurable airway responsiveness: a randomized placebo-controlled feasibility study

BACKGROUND: Epidemiological evidence suggests that hookworm infection protects against asthma. However, for ethical and safety reasons, before testing this hypothesis in a clinical trial in asthma it is necessary to establish whether experimental hookworm infection might exacerbate airway responsive...

Descripción completa

Detalles Bibliográficos
Autores principales: Feary, J, Venn, A, Brown, A, Hooi, D, Falcone, F H, Mortimer, K, Pritchard, D I, Britton, J
Formato: Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2728895/
https://www.ncbi.nlm.nih.gov/pubmed/19400893
http://dx.doi.org/10.1111/j.1365-2222.2009.03187.x
_version_ 1782170771670433792
author Feary, J
Venn, A
Brown, A
Hooi, D
Falcone, F H
Mortimer, K
Pritchard, D I
Britton, J
author_facet Feary, J
Venn, A
Brown, A
Hooi, D
Falcone, F H
Mortimer, K
Pritchard, D I
Britton, J
author_sort Feary, J
collection PubMed
description BACKGROUND: Epidemiological evidence suggests that hookworm infection protects against asthma. However, for ethical and safety reasons, before testing this hypothesis in a clinical trial in asthma it is necessary to establish whether experimental hookworm infection might exacerbate airway responsiveness during larval lung migration. OBJECTIVE: To determine whether hookworm larval migration through the lungs increases airway responsiveness in allergic individuals with measurable airway responsiveness but not clinical asthma, and investigate the general tolerability of infection and effect on allergic symptoms. METHODS: Thirty individuals with allergic rhinoconjunctivitis and measurable airway responsiveness to adenosine monophosphate (AMP) but not clinically diagnosed asthma were randomized, double-blind to cutaneous administration of either 10 hookworm larvae or histamine placebo, and followed for 12 weeks. The primary outcome was the maximum fall from baseline in provocative dose of inhaled AMP required to reduce 1-s forced expiratory volume by 10% (PD(10)AMP) measured at any time over the 4 weeks after active or placebo infection. Secondary outcomes included peak flow variability in the 4 weeks after infection, rhinoconjunctivitis symptom severity and adverse effect diary scores over the 12-week study period, and change in allergen skin test responses between baseline and 12 weeks. RESULTS: Mean maximum change in PD(10)AMP from baseline was slightly but not significantly greater in the hookworm than the placebo group (−1.67 and −1.16 doubling doses; mean difference −0.51, 95% confidence interval −1.80 to 0.78, P=0.42). Symptom scores of potential adverse effects were more commonly reported in the hookworm group, but infection was generally well tolerated. There were no significant differences in peak-flow variability, rhinoconjunctivitis symptoms or skin test responses between groups. CONCLUSION: Hookworm infection did not cause clinically significant exacerbation of airway responsiveness and was well tolerated. Suitably powered trials are now indicated to determine the clinical effectiveness of hookworm infection in allergic rhinoconjunctivitis and asthma.
format Text
id pubmed-2728895
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher Blackwell Publishing Ltd
record_format MEDLINE/PubMed
spelling pubmed-27288952009-08-27 Safety of hookworm infection in individuals with measurable airway responsiveness: a randomized placebo-controlled feasibility study Feary, J Venn, A Brown, A Hooi, D Falcone, F H Mortimer, K Pritchard, D I Britton, J Clin Exp Allergy Original Articles:Clinical Allergy BACKGROUND: Epidemiological evidence suggests that hookworm infection protects against asthma. However, for ethical and safety reasons, before testing this hypothesis in a clinical trial in asthma it is necessary to establish whether experimental hookworm infection might exacerbate airway responsiveness during larval lung migration. OBJECTIVE: To determine whether hookworm larval migration through the lungs increases airway responsiveness in allergic individuals with measurable airway responsiveness but not clinical asthma, and investigate the general tolerability of infection and effect on allergic symptoms. METHODS: Thirty individuals with allergic rhinoconjunctivitis and measurable airway responsiveness to adenosine monophosphate (AMP) but not clinically diagnosed asthma were randomized, double-blind to cutaneous administration of either 10 hookworm larvae or histamine placebo, and followed for 12 weeks. The primary outcome was the maximum fall from baseline in provocative dose of inhaled AMP required to reduce 1-s forced expiratory volume by 10% (PD(10)AMP) measured at any time over the 4 weeks after active or placebo infection. Secondary outcomes included peak flow variability in the 4 weeks after infection, rhinoconjunctivitis symptom severity and adverse effect diary scores over the 12-week study period, and change in allergen skin test responses between baseline and 12 weeks. RESULTS: Mean maximum change in PD(10)AMP from baseline was slightly but not significantly greater in the hookworm than the placebo group (−1.67 and −1.16 doubling doses; mean difference −0.51, 95% confidence interval −1.80 to 0.78, P=0.42). Symptom scores of potential adverse effects were more commonly reported in the hookworm group, but infection was generally well tolerated. There were no significant differences in peak-flow variability, rhinoconjunctivitis symptoms or skin test responses between groups. CONCLUSION: Hookworm infection did not cause clinically significant exacerbation of airway responsiveness and was well tolerated. Suitably powered trials are now indicated to determine the clinical effectiveness of hookworm infection in allergic rhinoconjunctivitis and asthma. Blackwell Publishing Ltd 2009-07 /pmc/articles/PMC2728895/ /pubmed/19400893 http://dx.doi.org/10.1111/j.1365-2222.2009.03187.x Text en © 2009 Blackwell Publishing Ltd http://creativecommons.org/licenses/by/2.5/ Re-use of this article is permitted in accordance with the Creative Commons Deed, Attribution 2.5, which does not permit commercial exploitation.
spellingShingle Original Articles:Clinical Allergy
Feary, J
Venn, A
Brown, A
Hooi, D
Falcone, F H
Mortimer, K
Pritchard, D I
Britton, J
Safety of hookworm infection in individuals with measurable airway responsiveness: a randomized placebo-controlled feasibility study
title Safety of hookworm infection in individuals with measurable airway responsiveness: a randomized placebo-controlled feasibility study
title_full Safety of hookworm infection in individuals with measurable airway responsiveness: a randomized placebo-controlled feasibility study
title_fullStr Safety of hookworm infection in individuals with measurable airway responsiveness: a randomized placebo-controlled feasibility study
title_full_unstemmed Safety of hookworm infection in individuals with measurable airway responsiveness: a randomized placebo-controlled feasibility study
title_short Safety of hookworm infection in individuals with measurable airway responsiveness: a randomized placebo-controlled feasibility study
title_sort safety of hookworm infection in individuals with measurable airway responsiveness: a randomized placebo-controlled feasibility study
topic Original Articles:Clinical Allergy
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2728895/
https://www.ncbi.nlm.nih.gov/pubmed/19400893
http://dx.doi.org/10.1111/j.1365-2222.2009.03187.x
work_keys_str_mv AT fearyj safetyofhookworminfectioninindividualswithmeasurableairwayresponsivenessarandomizedplacebocontrolledfeasibilitystudy
AT venna safetyofhookworminfectioninindividualswithmeasurableairwayresponsivenessarandomizedplacebocontrolledfeasibilitystudy
AT browna safetyofhookworminfectioninindividualswithmeasurableairwayresponsivenessarandomizedplacebocontrolledfeasibilitystudy
AT hooid safetyofhookworminfectioninindividualswithmeasurableairwayresponsivenessarandomizedplacebocontrolledfeasibilitystudy
AT falconefh safetyofhookworminfectioninindividualswithmeasurableairwayresponsivenessarandomizedplacebocontrolledfeasibilitystudy
AT mortimerk safetyofhookworminfectioninindividualswithmeasurableairwayresponsivenessarandomizedplacebocontrolledfeasibilitystudy
AT pritcharddi safetyofhookworminfectioninindividualswithmeasurableairwayresponsivenessarandomizedplacebocontrolledfeasibilitystudy
AT brittonj safetyofhookworminfectioninindividualswithmeasurableairwayresponsivenessarandomizedplacebocontrolledfeasibilitystudy